• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    11/28/23 4:31:03 PM ET
    $ATNF
    $BTTX
    $BWV
    $COCH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email

    Gainers

    • 180 Life Sciences (NASDAQ:ATNF) shares rose 38.2% to $0.47 during Tuesday's after-market session. The company's market cap stands at $3.4 million.
    • Redhill Biopharma (NASDAQ:RDHL) shares rose 23.34% to $2.8. The market value of their outstanding shares is at $30.9 million.
    • Trinity Biotech (NASDAQ:TRIB) stock rose 15.25% to $0.52. The company's market cap stands at $19.8 million.
    • Blue Water Biotech (NASDAQ:BWV) shares increased by 13.04% to $0.26. The market value of their outstanding shares is at $4.8 million.
    • CohBar (NASDAQ:CWBR) shares increased by 12.96% to $0.86. The market value of their outstanding shares is at $2.4 million.
    • DermTech (NASDAQ:DMTK) stock moved upwards by 9.58% to $1.83. The company's market cap stands at $62.6 million.

    Losers

    • GlucoTrack (NASDAQ:GCTK) stock fell 15.5% to $0.19 during Tuesday's after-market session. The company's market cap stands at $3.9 million.
    • Better Therapeutics (NASDAQ:BTTX) shares decreased by 9.43% to $0.19. The market value of their outstanding shares is at $8.8 million.
    • Verve Therapeutics (NASDAQ:VERV) shares decreased by 8.64% to $10.9. The company's market cap stands at $694.9 million.
    • Envoy Medical (NASDAQ:COCH) shares decreased by 7.91% to $1.63. The market value of their outstanding shares is at $31.8 million.
    • Sonnet BioTherapeutics (NASDAQ:SONN) stock fell 7.49% to $1.36. The company's market cap stands at $2.3 million.
    • Personalis (NASDAQ:PSNL) shares fell 6.06% to $1.55. The company's market cap stands at $76.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATNF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF
    $BTTX
    $BWV
    $COCH

    CompanyDatePrice TargetRatingAnalyst
    Envoy Medical Inc.
    $COCH
    3/31/2026$2.50Buy
    H.C. Wainwright
    Personalis Inc.
    $PSNL
    12/2/2025$11.00Equal-Weight
    Morgan Stanley
    Personalis Inc.
    $PSNL
    5/15/2025$6.00Buy
    Guggenheim
    Verve Therapeutics Inc.
    $VERV
    4/15/2025Neutral → Overweight
    Cantor Fitzgerald
    Personalis Inc.
    $PSNL
    3/17/2025$8.00Buy
    Canaccord Genuity
    Envoy Medical Inc.
    $COCH
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    Verve Therapeutics Inc.
    $VERV
    4/8/2024$15.00Buy
    H.C. Wainwright
    Verve Therapeutics Inc.
    $VERV
    4/13/2023$29.00Buy
    Canaccord Genuity
    More analyst ratings

    $ATNF
    $BTTX
    $BWV
    $COCH
    SEC Filings

    View All

    SEC Form DEFA14A filed by Personalis Inc.

    DEFA14A - Personalis, Inc. (0001527753) (Filer)

    4/2/26 4:07:10 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by Personalis Inc.

    DEF 14A - Personalis, Inc. (0001527753) (Filer)

    4/2/26 4:03:19 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Envoy Medical Inc.

    DEFA14A - Envoy Medical, Inc. (0001840877) (Filer)

    4/2/26 4:02:24 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $ATNF
    $BTTX
    $BWV
    $COCH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Personalis to Participate in the 25th Annual Needham Virtual Conference

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the 25th Annual Needham Virtual Conference on Wednesday, April 15, 2026. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at

    4/1/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Envoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear Implant

    Company Remains on Schedule for PMA Submission to FDAWhite Bear Lake, Minnesota--(Newsfile Corp. - April 1, 2026) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, announced that the first three patients implanted in its pivotal clinical trial for the fully implanted Acclaim® cochlear implant have successfully completed their 12-month endpoint visit, marking a key milestone in the study's progress.The first three pivotal trial patients implanted at the start of 2025 are now the first to reach the 12-month follow-up evaluation point. The primary endpoints for the trial are tied to 12-month data. Achieving this critic

    4/1/26 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

    Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued patents for Glucotrack's implantablecontinuous blood glucose monitoring (CBGM) technology, strengthening the Company'sintellectual property portfolio Rutherford, NJ, March 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year

    3/30/26 4:50:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $ATNF
    $BTTX
    $BWV
    $COCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Envoy Medical with a new price target

    H.C. Wainwright initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $2.50

    3/31/26 8:12:03 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Morgan Stanley resumed coverage on Personalis with a new price target

    Morgan Stanley resumed coverage of Personalis with a rating of Equal-Weight and set a new price target of $11.00

    12/2/25 8:29:48 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Guggenheim initiated coverage on Personalis with a new price target

    Guggenheim initiated coverage of Personalis with a rating of Buy and set a new price target of $6.00

    5/15/25 8:13:23 AM ET
    $PSNL
    Medical Specialities
    Health Care

    $ATNF
    $BTTX
    $BWV
    $COCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Murphy Paul

    3 - TRINITY BIOTECH PLC (0000888721) (Issuer)

    4/3/26 8:15:37 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Tivnan John Paul

    3 - TRINITY BIOTECH PLC (0000888721) (Issuer)

    4/3/26 8:14:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Gillard John

    3 - TRINITY BIOTECH PLC (0000888721) (Issuer)

    4/3/26 8:11:38 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ATNF
    $BTTX
    $BWV
    $COCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Kantor Susan bought $38,460 worth of shares (96,150 units at $0.40), increasing direct ownership by 123% to 174,037 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:47:12 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $ATNF
    $BTTX
    $BWV
    $COCH
    Financials

    Live finance-specific insights

    View All

    Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

    Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech's New York Reference Laboratory DUBLIN and NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a global diagnostics company, today announced successful results from a clinical study of a new, enhanced version of its EpiCapture™ prostate cancer test, engineered to deliver higher precision risk prediction of aggressive prostate cancer. This next-generation version of EpiCapture™ utilizes machine learning tools that integrate additional patient features, including patient ethnicity in conjunction with the DNA biomarkers

    3/23/26 9:23:07 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

    DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into a collaboration agreement with the University at Buffalo, New York ("UB"). The partnership focuses on advancing and commercializing a suite of proprietary biomarkers for the earlier and more accurate detection of Sjögren's Syndrome, one of the most common but underdiagnosed autoimmune diseases. This collaboration is a key strategic milestone in the continued expansion of Trinity Biotech's New York State Department of Health – appr

    3/18/26 8:30:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System

    Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has commenced the commercial rollout in Brazil of its updated laboratory blood glucose monitoring solution, the next‑generation HbA1c column system for its Premier Hb9210™ platform, following receipt of local regulatory approval. This approval enables the introduction of the Company's upgraded boronate affinity column

    3/12/26 9:00:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ATNF
    $BTTX
    $BWV
    $COCH
    Leadership Updates

    Live Leadership Updates

    View All

    Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

    Dr. Chen expands his leadership role to serve as President while continuing to serve as Chief Medical Officer (CMO), unifying R&D innovation with operational execution as Personalis defines the next era of ultrasensitive MRD testing Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role. The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market leader in Minimal Residual Disease (MRD) testing. Under Dr. Chen's scientific l

    3/17/26 4:00:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

    Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results

    11/13/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team

    RUTHERFORD, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Usman Latif, MD, MBA, has been named to Glucotrack's clinical advisory team, providing strategic counsel as the Company advances its epidural glucose monitoring applications alongside its continuous blood glucose monitor (CBGM). "Dr. Latif is a prominent pain management specialist and opinion leader with deep expertise in neuromodulation and treatment of Painful Diabetic Neuropathy (PDN). His exceptional knowledge in pain man

    10/29/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $ATNF
    $BTTX
    $BWV
    $COCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Verve Therapeutics Inc.

    SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)

    11/18/24 5:23:52 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

    SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)

    11/14/24 5:26:28 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by 180 Life Sciences Corp.

    SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)

    11/14/24 3:53:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care